HIMSMonday, 8 Jun 2026

Eucalyptus brand consolidation, short-seller positioning, a preview of the shareholder meeting and a snapshot of sell-side consensus

Eucalyptus brand consolidation, short-seller positioning, a preview of the shareholder meeting and a snapshot of sell-side consensus.

Breakdown: 1 Buy, 3 Outperform, 12 Hold, 1 Underperform
Canaccord: Maintains Buy, $32 target. Peptides are a $20 billion market, and a 1% share equals $200 million in extra revenue.
Consensus target: $27-28.70 (shares at $26.19, about 4-10% upside)
Coverage: 17 analysts
TIKR target: $39 (December 2030)

All Eucalyptus brands will be retired in favour of a single global Hims & Hers brand. That lowers operating costs but risks losing local users.
The peptide business is not going overseas for now, as international markets wait on the outcome of the FDA's 23 Jul review. That puts the three-year $1 billion international target under heavy pressure.
A new bear thesis on ValueInvestorsClub estimates 60% downside, though the author concedes there is a risk of a short squeeze.
Short interest is about 31% of the float. It has held steady since late April, with no new shorts added.
Insiders' buy-to-sell ratio over the past 3 months is 1:20 (net selling), but most of the sales were under pre-set 10b5-1 plans.
11 Jun annual shareholder meeting: the CEO's $22.96 million pay package (a pay ratio of 272:1) is a potential focus for negative headlines.

Show 2 more

Sell-side consensus: 17 analysts, with 1 Buy, 3 Outperform, 12 Hold and 1 Underperform. Price targets are $27-28.70.
TIKR's model target is $39 (December 2030). Canaccord maintains Buy with a $32 target.

Bear thesis: Pridwen's write-up on ValueInvestorsClub estimates 60% downside. The core argument is overvaluation, but it concedes the risk of a short squeeze.
Current: About 31% of the float
Trend: Steady since late April, no new shorts added

Outcome of the FDA's peptide review on 23 Jul, which will set the pace of international expansion
11 Jun annual shareholder meeting: result of the say-on-pay vote on CEO compensation
Progress on the Eucalyptus brand consolidation

A low approval rate in the CEO pay vote could spark a negative narrative in the short term
Retiring the local Eucalyptus brands could cost users in Australia and the UK
The three-year $1 billion international revenue target is under heavy pressure while peptides stay out of overseas markets
Continued net selling by insiders

Sources 1

A brief is a lead for our research, not a verified conclusion or advice.